Compositions and methods for cancer treatment using targeted carbon nanotubes
Patent Number: US8518870
Executive Summary:
General Description:
Photodynamic therapy is based on the concept that light irradiation can change an inert substance to an active one and holds great promise for the treatment of cancer. T specific light-sensitive agent can be administered to the cancer patient, and light of a specific wavelength activates this compound, resulting in a cytotoxic reaction and the destruction of cancer cells. To prevent cytotoxic side-effects, the current invention describes the association of such light-sensitive compound with a protein that directly binds to the tumor.
Strengths:
Weaknesses:
Patent Status:
Inventor Bio: Roger G. Harrison
http://www.ou.edu/coe/cbme/people/faculty1/harrison.html
Executive Summary:
- Invention Type: Therapeutic
- Patent Status: Active
- Patent Link: https://patents.google.com/patent/US8518870/
- Research Institute: University of Oklahoma
- Disease Focus: Breast cancer
- Basis of Invention: Therapeutic proteins linked to carbon nanotubes
- How it works: A linking protein or protein peptide, such as Annexin V, is associated with single-walled carbon nanotubes. Annexin V specifically binds external receptors on the vasculature endothelium of a cancer cell, resulting in the location of the single-walled carbon nanotube at the outer surface of the tumor. Exposure of electromagnetic radiation, comprising a wavelength that is absorbed by the single-walled carbon nanotube, results in the destruction of the tumor vasculature
- Lead Challenge Inventor: Roger G. Harrison
- Inventors: Roger G. Harrison, Jr., Daniel E. Resasco, Luis Filipe Ferreira Neves
- Development Stage: Pre-clinical
- Novelty:
- Use of single-walled carbon nanotubes
- Clinical Applications:
- Specific detection and destruction of tumor cells using photodynamic therapy
- Specific detection and destruction of tumor cells using photodynamic therapy
General Description:
Photodynamic therapy is based on the concept that light irradiation can change an inert substance to an active one and holds great promise for the treatment of cancer. T specific light-sensitive agent can be administered to the cancer patient, and light of a specific wavelength activates this compound, resulting in a cytotoxic reaction and the destruction of cancer cells. To prevent cytotoxic side-effects, the current invention describes the association of such light-sensitive compound with a protein that directly binds to the tumor.
Strengths:
- Improved treatment efficacy and toxicity compared to systemic approaches
- Tumor specific
- Lower dosages and lower toxicity
Weaknesses:
- Two-step approach (drug delivery + irradiation)
Patent Status:
- Filing date: 2009-11-13
Inventor Bio: Roger G. Harrison
http://www.ou.edu/coe/cbme/people/faculty1/harrison.html
